NTC 121Alternative Names: NTC-121
Latest Information Update: 08 Oct 2002
At a glance
- Originator Neurotech SA
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 23 Aug 2002 Discontinued - Phase-II for Glioma in France (unspecified route)
- 19 Dec 2000 NTC 121 is available for licensing (http://www.neurotech.fr)
- 15 May 2000 Phase-II clinical trials for Glioma in France (Unknown route)